K.W. is a member of the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. In the past 36 months, its activities were supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi and Otsuka. J.L.M. is a consultant for GlaxoSmithKline. B.P.L. is a consultant for GlaxoSmithKline, Novo Nordisk and HepaTX. M.C.M. is a consultant for GlaxoSmithKline, Prodigy, HepaTX and a Board member of Amygdala Neuroscience; there is research support to his institution from Durect. The other authors declare no competing interests.